Literature DB >> 10933322

Fatal deterioration of neurological disease after orthotopic liver transplantation for valproic acid-induced liver damage.

N Kayihan1, I Nennesmo, B G Ericzon, A Németh.   

Abstract

We describe a 12-year-old girl with an early onset neurologic disease of slow progressiveness and electro-encephalography showing epileptic activity. The girl developed fulminant liver failure 5 months after the start of valproic acid treatment. Repeated mitochondrial assays failed to prove a mitochondrial disorder, but muscle biopsies were slightly pathological. Liver histology indicated acute-on-chronic liver disease. Six weeks after a successful orthotopic liver transplantation her neurological condition deteriorated rapidly, soon leading to generalized cortical disease and death. Post-mortem brain examination showed advanced central nervous destruction. We suggest that this is a late-onset Huttenlocher variant of Alpers' syndrome, where fulminant liver failure can be triggered by valproic acid, and orthotopic liver transplantation can subsequently trigger a fatal neurologic deterioration. Our case illustrates that when a referral center receives a previously unknown patient with hepatocellular insufficiency, it might be impossible to differentiate between fulminant vs. acute-on-chronic liver failure, and the decision whether to perform a liver transplantation or not would become difficult.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933322     DOI: 10.1034/j.1399-3046.2000.00115.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  8 in total

Review 1.  Mitochondrial disorders of DNA polymerase γ dysfunction: from anatomic to molecular pathology diagnosis.

Authors:  Linsheng Zhang; Sherine S L Chan; Daynna J Wolff
Journal:  Arch Pathol Lab Med       Date:  2011-07       Impact factor: 5.534

2.  Mitochondrial respiratory chain hepatopathies: role of liver transplantation. A case series of five patients.

Authors:  Elisabeth De Greef; John Christodoulou; Ian E Alexander; Albert Shun; Edward V O'Loughlin; David R Thorburn; Vicki Jermyn; Michael O Stormon
Journal:  JIMD Rep       Date:  2011-11-04

3.  Complete Deletion of a POLG1 Allele in a Patient with Alpers Syndrome.

Authors:  Karin Naess; Michela Barbaro; Helene Bruhn; Rolf Wibom; Inger Nennesmo; Ulrika von Döbeln; Nils-Göran Larsson; Antal Nemeth; Nicole Lesko
Journal:  JIMD Rep       Date:  2011-10-20

4.  Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase γ (POLG1).

Authors:  R McFarland; G Hudson; R W Taylor; S H Green; S Hodges; P J McKiernan; P F Chinnery; V Ramesh
Journal:  BMJ Case Rep       Date:  2009-05-10

5.  Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States.

Authors:  Ayse L Mindikoglu; Dale King; Laurence S Magder; John A Ozolek; George V Mazariegos; Benjamin L Shneider
Journal:  J Pediatr       Date:  2010-12-16       Impact factor: 4.406

Review 6.  Gastrointestinal and hepatic manifestations of mitochondrial disorders.

Authors:  Shamima Rahman
Journal:  J Inherit Metab Dis       Date:  2013-05-15       Impact factor: 4.982

Review 7.  POLG-related disorders and their neurological manifestations.

Authors:  Shamima Rahman; William C Copeland
Journal:  Nat Rev Neurol       Date:  2019-01       Impact factor: 42.937

Review 8.  Syndromes associated with mitochondrial DNA depletion.

Authors:  Célia Nogueira; Ligia S Almeida; Claudia Nesti; Ilaria Pezzini; Arnaldo Videira; Laura Vilarinho; Filippo M Santorelli
Journal:  Ital J Pediatr       Date:  2014-04-03       Impact factor: 2.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.